GLSICorporate•globenewswire•
Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events
Sentiment:Negative (30)
Summary
STAFFORD, Texas, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following update on CEO interviews and corporate events.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 11, 2025 by globenewswire